MarketCap
Facebook
X
Telegram
Aeterna Zentaris Market Cap | AEZS
As of October 27, 2026 Aeterna Zentaris has a market cap of $ 314 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Aeterna Zentaris
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 14.8 M | 3.66 M | 5.02 M | 41.4 M | 28.3 M | 18.7 M | 63 M | 32.3 M | 26.9 M | 3.99 B | 31.3 M | 38.6 M | 59.9 M | 158 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.99 B | 3.66 M | 322 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
50 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
26.1 M | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
68.4 M | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
310 M | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
17 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
20.5 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
48.5 K | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
311 M | - | - | $ 24.9 M | USA |
 |
Завод ДИОД
DIOD
|
661 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
2 B | - | - | - | Russia |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
541 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
73.5 M | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
179 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
101 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
2.98 B | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
47.3 M | - | - | $ 2.36 B | USA |
 |
Exicure
XCUR
|
29 M | $ 1.09 | 3.81 % | $ 6.86 M | USA |
 |
Cellectis S.A.
CLLS
|
335 M | $ 0.95 | -3.3 % | $ 95.3 M |  France |
 |
AbCellera Biologics
ABCL
|
962 M | $ 12.03 | 1.78 % | $ 3.59 B | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
6.25 B | $ 58.93 | 1.57 % | $ 7.88 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
11.7 B | $ 55.62 | -0.59 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
2.04 B | $ 29.48 | 0.79 % | $ 1.96 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
4.64 M | $ 3.75 | 2.18 % | $ 45.8 M |  Israel |
 |
Jaguar Health
JAGX
|
956 K | $ 2.36 | 15.44 % | $ 5.5 M | USA |
 |
Protalix BioTherapeutics
PLX
|
174 M | $ 2.49 | -2.35 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
626 M | $ 21.65 | -3.5 % | $ 1.24 B | Niderland |
 |
Stoke Therapeutics
STOK
|
2.01 B | $ 25.41 | 1.48 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
892 M | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Annexon
ANNX
|
769 M | $ 3.71 | -1.2 % | $ 575 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 1.71 | -4.21 % | $ 2.82 M | Israel |
 |
Incyte Corporation
INCY
|
19.5 B | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
2.04 B | $ 12.43 | 1.22 % | $ 15 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
651 M | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
125 B | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Burford Capital Limited
BUR
|
2.78 B | $ 3.24 | -3.72 % | $ 710 M |  Britain |
 |
Catalyst Biosciences
CBIO
|
999 M | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
214 M | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
206 M | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
Evogene Ltd.
EVGN
|
6.38 M | $ 0.37 | 0.44 % | $ 2.91 M | Israel |
 |
EyePoint Pharmaceuticals
EYPT
|
1.15 M | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
77.8 M | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
169 M | $ 10.12 | 0.4 % | $ 289 M | USA |
|
Foghorn Therapeutics
FHTX
|
356 M | $ 2.04 | 2.0 % | $ 128 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
12.3 B | $ 13.76 | 4.13 % | $ 11.5 B |  India |